Today's Peptide News — September 16, 2026

Researchers built a computational pipeline that scans the human proteome for prohormones and predicts where enzymes cleave them, then screened the resulting fragments for metabolic activity. The approach surfaced a previously uncharacterized peptide, dubbed BRP, that suppresses food intake and reduces body weight in mice and pigs without acting through the GLP-1 receptor or the other incretin pathways that dominate today's obesity drugs.

The finding matters because nearly every blockbuster weight-loss agent works through the same handful of gut-hormone receptors, which shapes both their side-effect profiles and their competitive crowding. A peptide that curbs appetite through an independent mechanism opens a fresh pharmacological lane and hints that the human peptidome still hides untapped endogenous regulators of energy balance.

A good PeptideWiki angle: a short explainer on BRP as a case study in "hormone mining" — how prediction of prohormone cleavage sites is becoming a discovery engine, and why a non-incretin mechanism could complement rather than compete with GLP-1 therapies.

Chemists have described a peptide-drug conjugate that engages five distinct pathways at once, pairing agonism at the GLP-1, GIP and glucagon receptors with a PPAR-modulating small-molecule payload tethered to the peptide backbone. In preclinical models the quintuple-action molecule drove potent weight and glucose control while the design aimed to keep the safety margin favorable.

It matters as a proof of concept that a single conjugate can span both incretin biology and nuclear-receptor metabolism, potentially collapsing what would otherwise be a drug cocktail into one agent. The strategy also showcases how peptides are increasingly used as targeting and multiplexing scaffolds rather than standalone actives.

A good PeptideWiki angle: a primer on peptide-drug conjugates as a format — how a peptide can serve as both a receptor agonist and a delivery vehicle for a small-molecule cargo, using this five-target molecule as the illustration.

A bioRxiv preprint reports a retro-inverso peptide — a mirror-image sequence built from D-amino acids in reversed order — that both blocks the formation of alpha-helical amyloid and breaks apart preformed Staphylococcus aureus biofilms. Because the retro-inverso design resists the proteases that rapidly degrade ordinary peptides, the molecule retained activity where conventional peptides would be chewed up.

The result is notable for biofilm-associated MRSA infections, which are among the hardest to treat because the biofilm matrix shields bacteria from antibiotics and immune clearance. A protease-stable peptide that dismantles that matrix could become a template for anti-biofilm therapeutics.

A good PeptideWiki angle: an explainer on the retro-inverso trick — what D-amino acids and reversed sequences do for stability, and why that chemistry is so attractive for anti-biofilm and anti-amyloid peptides.

Working from a naturally occurring template, researchers generated a focused library of roughly twenty peptide variants and identified several with enhanced, dual-mechanism antibacterial activity against clinically important pathogens including Escherichia coli, Klebsiella pneumoniae, Staphylococcus aureus and the fungus Candida albicans. The best variants combined membrane disruption with a second mode of action, a pairing thought to slow the emergence of resistance.

With antimicrobial resistance climbing, peptides that kill through more than one mechanism are prized because bacteria must clear two hurdles at once to survive. Iterating on a nature-derived scaffold is a pragmatic route to candidates that keep the potency of natural host-defense peptides while improving selectivity.

A good PeptideWiki angle: a short post on why "dual-mechanism" is the sought-after property in antimicrobial peptide design, framed around this scaffold-optimization study.

CagriSema — Novo Nordisk's once-weekly fixed-dose combination of the GLP-1 agonist semaglutide and the amylin analog cagrilintide — has finished its pivotal program and now sits under FDA review, with an approval decision expected around October. In the REDEFINE-1 trial the combination produced about 22.7% weight loss in obesity, and reports credit it with helping preserve bone and lean body mass while improving several cardiovascular risk factors.

An approval would make CagriSema one of the first combination peptide therapies to pair incretin and amylin biology in a single injection, sharpening the competitive picture against tirzepatide and the next wave of triple agonists.

A real-world analysis of electronic records from more than 80,000 UK patients, presented at the European Respiratory Society Congress, found that semaglutide use was associated with nearly 40% fewer asthma attacks and about 20% fewer COPD exacerbations compared with other diabetes treatments. Notably, older GLP-1 drugs such as liraglutide, dulaglutide and exenatide showed no comparable respiratory benefit, pointing to possible within-class differences.

The signal adds respiratory disease to the lengthening list of conditions where GLP-1 therapies may help beyond diabetes and weight, though the researchers stress the study is observational and that randomized trials are needed before anyone is prescribed semaglutide for lung disease.

A retrospective cohort of 486 adults treated at a Vienna obesity clinic between 2022 and 2025 found that 80–85% of the weight lost on GLP-1 or GIP/GLP-1 receptor agonists came from fat mass, with relative muscle mass largely preserved. Fat mass tracked closely with absolute skeletal muscle, suggesting proportional changes in body composition rather than the disproportionate muscle wasting some clinicians have feared.

The data, presented at the European Congress on Obesity, help address one of the loudest criticisms of incretin-based weight loss and reinforce the case that quality of weight loss, not just quantity, deserves attention as these drugs reach ever more patients.

Analyzing 112,284 participants from the Nurses' Health Study and Health Professionals Follow-Up Study, Mass General Brigham researchers found that people who drank at least one sugar-sweetened beverage a day had roughly 2.45 times the risk of gastric cancer versus those who rarely did. Artificially sweetened drinks carried no such association, and higher fructose intake tracked with more cancer cases.

Published in Gastro Hep Advances, it is described as the first study to link sugar-sweetened beverage intake to gastric cancer in a US population. The design is observational, so it can show correlation rather than prove that sugary drinks cause stomach cancer, but the size and duration of the cohorts give the signal weight.

The USDA has confirmed the first domestic detections of New World screwworm in nearly 60 years, with cases in South Texas and additional counties in Texas and New Mexico. The parasite, whose larvae burrow into and consume the living tissue of animals and occasionally people, reemerged in southern Mexico in late 2024 and has spread steadily north.

The return threatens livestock, wildlife and pets, echoing an era when screwworm cost US producers tens of millions of dollars a year before it was eradicated and pushed south to Panama. Officials have launched a tracking dashboard and response effort as they work to keep the outbreak from establishing itself.

Scientists have found that senescent "zombie" cells exploit malfunctioning mitochondria to switch on inflammatory genes and lock the immune system into a prolonged state of alert. Damaged mitochondria leak DNA and RNA into parts of the cell where that genetic material does not belong, and the immune system reads the misplaced molecules as a danger signal — with two separate mitochondrial processes converging to both expose the inflammatory genes and provide the trigger to activate them.

Blocking one arm of this process reduced inflammation and improved healthy aging in mice, hinting at a new strategy against the chronic, low-grade inflammation that accompanies aging and drives many age-related diseases.